The burden of asthma and chronic obstructive pulmonary disease: Data from the Netherlands

PharmacoEconomics

Volumn 19, Issue SUPPL. 2, 2001, Pages 1-6

  Rutten Van Molken M P M H ^a   Feenstra, T L ^b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; RESPIRATORY TRACT AGENT;

AGING; ASTHMA; BUDGET; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; COST OF ILLNESS; DECISION MAKING; DRUG COST; ECONOMIC EVALUATION; FEMALE; GOVERNMENT; HOSPITALIZATION; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NETHERLANDS; POPULATION RISK; PREVALENCE; PRIORITY JOURNAL; RESOURCE ALLOCATION; SMOKING HABIT; TREATMENT OUTCOME;

EID: 0034788633     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119002-00001     Document Type: Conference Paper

References (8)

1. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands
2. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study
3. The impact of aging and smoking on the future burden of COPD: A model analysis in the Netherlands
4. What our practices teach us
5. Episode of care: A core concept in family practice
6. Chronic illness in the community and the concept of social prevalence
7. The prevalence of COPD: Using smoking rates to estimate disease frequency in the general population